Dr. Alessandra Magnani is a pediatric immunologist and researcher with extensive expertise in Inborn Errors of Immunity (IEI), Hematopoietic Stem Cell Transplantation (HSCT), and gene therapy (GT). She earned her MD from the University of Pavia, Italy, and completed her Pediatrics specialization in 2009 at the Gaslini Institute in Genoa and Necker-Enfants Malades Hospital in Paris, where she focused on IEI and HSCT under the mentorship of Prof. Alain Fischer. From 2010 to 2013, she pursued a PhD in Genetics and Immunology at the University of Genoa and the Novartis Institutes for Biomedical Research in Basel, Switzerland. Between 2014 and 2022, Dr. Magnani served as Medical Director at the Cell and Gene Therapy Laboratory at Necker-Enfants Malades Hospital led by Pr Cavazzana, overseeing the production of cellular products and the development and manufacturing of Advanced Therapy Medicinal Products (ATMPs). Here she gained significant experience in the development of Phase I/II clinical trials targeting inborn errors of immunity (IEI) and hemoglobinopathies, including Severe Combined Immunodeficiency (SCID)-X1, Wiskott-Aldrich Syndrome, X-linked Chronic Granulomatous Disease, Artemis-SCID, Sickle Cell Disease, and Beta-thalassemia. As a project leader and pediatric immunologist, she was also responsible for the clinical and biological follow-up of gene therapy patients. For over 15 years, Dr. Magnani has been actively engaged in international scientific societies and has contributed to several European consortia on gene therapy in IEI. She has consistently contributed to the scientific community through publications in internationally recognized peer-reviewed journals, as well as through teaching, thesis supervision, educational programs, and initiatives aimed at promoting public understanding of science. In 2022, Dr. Magnani joined the Barcelona Children Hospital Sant Joan de Déu as Head of the Advanced Therapies Platform, a newly established GMP facility focused on the research, development and production of ATMPs for pediatric patients affected with rare diseases. Since 2024, she is Vice-Coordinator of the European Reference Network (ERN-RITA) for rare immunologic disorders.